Chat with Filing

Ask questions about this document

Please log in or register to use the chat feature. Please register first.

RPA - BB Biotech AG publishes its 2024 annual report

Company: BB Biotech AG Date: 2025-02-21 Language: English Register to download

Loading document preview...

Document Preview Not Available

The file type (.html) cannot be displayed directly here.

Open Original File

Error loading document preview. Please try the 'Open Original File' link.

You're One Click Away From The Full Filing

Instantly access this document—and 2.8M more—for free. Select your preferred method:

Continue with Google Continue with Microsoft Continue with Facebook Continue with Amazon

 News Details

Ad-hoc | 21 February 2025 07:00

#   

BB Biotech AG publishes its 2024 annual report

BB BIOTECH AG / Key word(s): Annual Report/Dividend  

BB Biotech AG publishes its 2024 annual report  

  

21-Feb-2025 / 07:00 CET/CEST  

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group.  

The issuer is solely responsible for the content of this announcement.  

  

- - -

Ad hoc announcement pursuant to Art. 53 LR

February 21, 2025

Annual report of BB Biotech AG as at December 31, 2024

**BB Biotech AG publishes its 2024 annual report**

BB Biotech AG published its annual report for fiscal year 2024 today. Besides the audited consolidated financial statements, the annual report contains detailed information on the biotechnology sector, BB Biotech’s positioning, the investment areas covered by its portfolio and the companies it is invested in.

In 2024, BB Biotech AG shares delivered a total return of -13.5% in CHF and -14.1% in EUR, including the CHF 2.00 dividend paid in March 2024. Our Net Asset Value (NAV) performance showed greater resilience, increasing by 3.0% in CHF and 1.7% in EUR for the year, while declining by 4.6% in USD. For the full year 2024, BB Biotech AG recorded a net profit of CHF 76 mn compared to a net loss of CHF 207 mn in 2023.

As already announced on January 24, 2025, BB Biotech AG will propose a dividend of CHF 1.80 per share at the upcoming Annual General Meeting, which represents a yield of 5% based on the volume-weighted average price of BB Biotech AG shares in December 2024. This marks a continuation of the dividend policy of the previous years.

BB Biotech’s annual report 2024 is available under **[report.bbbiotech.ch/2024/en](https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=e1116fb7b2060930e8fbc29738aa01eb&application_id=2089337&site_id=airport_aws~~~7cc68db1-74de-43c8-af69-2ae0a97efdc3&application_name=news)** resp. **[www.bbbiotech.com](https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=e095f2ad7eb33d4b529fa6d07922a358&application_id=2089337&site_id=airport_aws~~~7cc68db1-74de-43c8-af69-2ae0a97efdc3&application_name=news)**

  

**For further information:**

Bellevue Asset Management AG, Theaterstrasse 12, 8001 Zurich, Switzerland, tel. +41 44 267 67 00

**Head Investment Management Team BB Biotech**  

Dr. Christian Koch  

  

**Investor Relations**  

ir@bbbiotech.com  

Dr. Silvia Siegfried-Schanz, ssc@bellevue.ch  

Maria-Grazia Alderuccio, mga@bellevue.ch  

Claude Mikkelsen, cmi@bellevue.ch

**Media Relations**  

Tanja Chicherio, tch@bellevue.ch

[www.bbbiotech.com](https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=8f199a071872bd0aa9567229880059fd&application_id=2089337&site_id=airport_aws~~~7cc68db1-74de-43c8-af69-2ae0a97efdc3&application_name=news)

**Company profile**  

BB Biotech AG is an investment company with its registered office in Schaffhausen/Switzerland and listed on the Swiss and German stock exchanges. It has invested in innovative drug developers headquartered primarily in the US and Western Europe. BB Biotech is one of the world’s largest investors in this sector. The competent Board of Directors with its long-standing experience set the investment strategy and guidelines. Investment decisions are taken by the experienced investment management team of Bellevue Asset Management AG based on their extensive investment research.

  

  

End of Inside Information  

- - -

21-Feb-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.  

Archive at www.eqs-news.com  

- - -

|     |     |
| --- | --- |
| Language: | English |
| Company: | BB BIOTECH AG |
|     | Schwertstrasse 6 |
|     | 8200 Schaffhausen |
|     | Switzerland |
| Phone: | +41 52 624 08 45 |
| E-mail: | info@bbbiotech.com |
| Internet: | www.bbbiotech.ch |
| ISIN: | CH0038389992 |
| WKN: | A0NFN3 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Mailand, SIX |
| EQS News ID: | 2089337 |

  

|     |     |
| --- | --- |
|     |     |
| End of Announcement | EQS News Service |

- - -

2089337  21-Feb-2025 CET/CEST

![fncls.ssp?fn=show_t_gif&application_id=2089337&application_name=news&site_id=airport_aws~~~7cc68db1-74de-43c8-af69-2ae0a97efdc3](https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=2089337&application_name=news&site_id=airport_aws~~~7cc68db1-74de-43c8-af69-2ae0a97efdc3)